Puxi-samsaruparibrilvegostomigInstitutional Animal Care and Use Committee of Astrazeneca
…ceive either monotherapy doublet or triple combination therapy. Puxi-sam was administered as a single i.v. dose at 7 mg/kg, saruparib wa…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 721–780 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Dapsone5Diclofenac5Epirubicin5FibroScan5Hyperbaric bupivacaine5ICB5ICS/LABA5IFNγ5IL-185SARS-CoV-25donanemab5immunomodulators5low-dose aspirin5tapentadol5thiazolidinediones56-mercaptopurine5High-dose steroids5JAK inhibitors5Letrozole5Mercaptopurine5Steroid5Trastuzumab Emtansine5Vitamin B125antiseizure medication5candesartan5ganciclovir5immune checkpoint inhibitor5non-steroidal anti-inflammatory drug5normal saline5nortriptyline5supplemental oxygen5ASMs5Atracurium5Bacillus Calmette-Guérin5Bendamustine5High-dose intravenous methylprednisolone5SF-365Selective Serotonin Reuptake Inhibitors5acetic acid5contraceptives5delpar5intravenous ceftriaxone5liposomal amphotericin B5prescription opioids5topical corticosteroids5venlafaxine5DPP4i4ELA4Estrogen4Rilvegostomig4HM163904Alectinib4Penumbra4RP14LEvoSimendan4Nipocalimab4Dinutuximab4SEL4BLM4IL-17i4
Articles mentioning drugs
10,506 articles · page 103 of 876WBMP-4IgM-expressing B-cell malignanciesWelt Bio-Molecular Pharmaceutical
…hibition and ADCC to be achieved by one modality. Our lead mAb, WBMP-4, binds to membrane-bound IgM, within the B-cell Receptor (BCR),…
artLCMV-NanoLucartLCMV.FRαartLCMVIL12artLCMV.gp70peritoneal carcinomatosisPC
…s Our results showed that the intraperitoneal administration of artLCMV-NanoLuc achieved sustained transgene expression in the peritoneal cavit…
VAX014VAX014-treatedSan Diego State Universitygastric cancerbladder cancer
…, Nelson K, Proclivo VH, McGuire KL, Giacalone MJ. Intravesical VAX014 synergizes with PD-L1 blockade to enhance local and systemic co…
VacV000PembrolizumabnivolumabQMULOestrogen receptor-positive (ER+) breast cancer (BC)ICR Flow Cytometry Facilitychemotherapy-ICI combinationsBreast Cancer Now Histopathology Core Facilitybreast cancer
…dscape of ER+ BC. By converting ‘cold’ tumours into ‘hot’ ones, VacV000 holds promise for synergistic use with other immunotherapies.Ac…
B10G5B10G5-treatedB10G5-mediatedsMICsolid tumorsNorthwestern Universityprostate tumors
… diminished functional heterogeneity of intra-tumoral NK cells. B10G5 treatment enriched a TCF1-hi stem-like NK reservoir and thereby…
HCW11-018bTCEPancreatic cancerSCID micePC
… injection of either human PBMC or purified T cells followed by HCW11-018b (1mg/kg, s.c.) the following day. Treatments were administered …
TCEsBiTcoCD2 BiTcoblood cancersEtablissement Français du Sang
…Background T cell engagers (TCEs) are clinically successful bispecific antibodies, albeit primar…
hAbChAbCshepatocellular carcinomaUniversity of WashingtonFred Hutch Cancer Centerimmune checkpoint blockade
…of DC and CD4+ T cells were also identified at various doses of hAbC (figure 2). Co-culture of DCs and CD4+ T cells lead to modulati…
TriAb4-1BBsolid tumors
…tion of anti-apoptotic markers in T cells. In xenograft models, TriAb significantly inhibited tumor growth, enhanced T cell prolifera…
AADDD-dimerOxford University Hospitalspulmonary embolism
…multiplier adjustments to improve clinical utility. Adoption of AADD with a ×11 multiplier could enhance cost-effectiveness and pati…